[TC-DC] The use of autologous Thrombo-Cytes for induction of Dendritic Cell activity

Invention

The therapeutic use of dendritic cells in vaccination approaches requires prior activation of these immune cells. The invention exploits the power of stimulated thrombocytes to activate dendritic cells ex vivo thereby offering the unique opportunity of autologous activation Commercial opportunity Immune therapy with activated dendritic cells is a well established methodology used for various indications and also for cancer vaccination strategies. Therefore the market potential is enormous. The technology offered is the first autologous one to mature dendritic cells into potent antigen presenting cells capable of optimal induction of T-cell responses. The simple and efficient activation strategy is strikingly simple to handle and compatible to established immunotherapy protocols. Current status An EU patent for TC-DC claiming priority from a German national application has been filed with the European Patent Office in March 2003. The European Patent has been granted in October 2006. It is being validated in Switzerland, Germany, France, Great Brittain and Italy. On behalf of the University Duisburg-Essen, PRO-vendis offers licences for TC-DC, options for their analysis and the opportunity for further co-development.

Further Information: PDF

PROvendis GmbH
Phone: +49 (0)208/94105 0

Contact
Dipl.-Ing. Alfred Schillert